Protamed, Inc.
Records under this name other than patents Protamed, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 6,929,808 | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants Term ended Term ended Nov 2, 2021 · From the USPTO record | Term ended | Term ended Nov 2, 2021 | From the USPTO record |
| US 8,563,590 | Compounds, compositions and methods for the treatment of islet amyloid polypeptide (IAPP) accumulation in diabetes Lapsed on the fee record Ended Oct 22, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 22, 2021 | From the USPTO record |
| US 7,601,876 | Compounds, compositions and methods for the treatment of amyloid diseases such as systemic AA amyloidosis Lapsed on the fee record Ended Oct 13, 2021 · From the USPTO record | Lapsed on the fee record | Ended Oct 13, 2021 | From the USPTO record |
| US 8,455,687 | Compounds and compositions for use as modulators of tau aggregation and alleviation of tauopathies Lapsed on the fee record Ended Jun 4, 2021 · From the USPTO record | Lapsed on the fee record | Ended Jun 4, 2021 | From the USPTO record |
| US 7,514,583 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease Lapsed on the fee record Ended Apr 7, 2021 · From the USPTO record | Lapsed on the fee record | Ended Apr 7, 2021 | From the USPTO record |
| US 9,469,605 | Compounds and compositions for use a modulators of tau aggregation and alleviation of tauopathies Lapsed on the fee record Ended Oct 18, 2020 · From the USPTO record | Lapsed on the fee record | Ended Oct 18, 2020 | From the USPTO record |
| US 9,334,251 | Compounds for the treatment of neurodegenerative diseases Lapsed on the fee record Ended May 10, 2020 · From the USPTO record | Lapsed on the fee record | Ended May 10, 2020 | From the USPTO record |
| US 8,163,957 | Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes and parkinson's disease Lapsed on the fee record Ended Apr 24, 2020 · From the USPTO record | Lapsed on the fee record | Ended Apr 24, 2020 | From the USPTO record |
| US 7,314,642 | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from Uncaria tomentosa and related plants Lapsed on the fee record Ended Jan 1, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jan 1, 2020 | From the USPTO record |
| US 9,169,255 | Caffeinated compounds and compositions for treatment of amyloid diseases and synucleinopathies Lapsed on the fee record Ended Oct 27, 2019 · From the USPTO record | Lapsed on the fee record | Ended Oct 27, 2019 | From the USPTO record |